Ken H Young, MD, PhD
Ken H Young, MD, PhD
Professor of Hematopathology
  • :(713) 745-2598
  • :(713) 792-7273

The University of Texas MD Anderson Cancer Center
Houston, TX


  1984   Zhejiang University School of Medicine, Zhejiang, China, MD
  1995   University of Lund School of Medicine, Malmo, Sweden, PhD
1995 -1999   Research Fellowship, Cardiovascular Hematology Program, University of Oklahoma Health Science Center, Oklahoma City


In University of Texas, Ken H. Young, MD PhD is an Associate Professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. He was Medical Director of Hematology at the University of Wisconsin School of Medicine and University East & West Clinic Laboratories, overseeing the laboratories at the University of Wisconin Hospital and Clinics Core Laboratory. He received his PhD from University of Lund School of Medicine and completed his MD training from Oregon Health Science University. He is board certified in Anatomic and Clinical Pathology and Hematopathology.


Research Interest

His interests are to characterize molecular defects in patients with leukemia and lymphoma by using gene expression profiling, immunophenotypic method, methylation-microRNA-CGH arrays and current NGS molecular technologies with particular interest in tumor suppressor genes, oncogenes, p53 and NF-kB pathways. He has worked extensively on molecular diagnostics for human cancer and has obtained several novel discoveries valuable to predict treatment response, clinical outcome and survival in cancer patients.


Professional Activities:

Professional Memberships/Activities

Professional Society Activities, with Offices Held
National and International

American Association for the Advancement of Science (AAAS) Member, 1996-2000
New York Academy of Science (NYAS) Member, 1996-2000
American Society of Clinical Pathologists (ASCP) Member, 2000-present
College of American Pathologists (CAP) Member, 2000-present
United States and Canadian Academy of Pathology (USCAP) Member, 2001-present
University of Wisconsin Institute for Clinical and Translational Research (ICTR) Member, 2005-2010
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Member, 2005-2010
American Society of Hematology (ASH) Member, 2005-present
American Society of Hematopathology (SH) Member, 2005-present


Honors and Awards

Honors And Awards

Graduate Student Research Scholar Award, Lund University School of Medicine, 1995
Howard Hughes Medical Institute Fellowship Award in Cardiovascular-Hematology Program, University of Oklahoma Health Science Center, 1996
Young Scholar Award, 1998 Annual Gordon Conference, 1998
Gundersen Medical Foundation Award, Gundersen Medical Foundation/Hospital, 2007
Lymphoma Research Foundation Award, Lymphoma Research Foundation, 2007
University of Wisconsin Cancer Center Harold Rusch Award, University of Wisconsin,
2007 Forward Lymphoma Research Award, Wisconsin Paul P. Carbone Cancer Center,
2008 IRG Award, 1st, The University of Texas MD Anderson Cancer Center, 2011-2013
Lymphoma SPORE DRP Award, The University of Texas MD Anderson Cancer Center, 2011-2013 Myeloma SPORE 1st DRP Award, The University of Texas MD Anderson Cancer Center,
2011-2013 IRG Award, 2nd, The University of Texas MD Anderson Cancer Center, 2014-2015
Myeloma SPORE 2nd DRP Award, The University of Texas MD Anderson Cancer Center, 2014-2015


Peer-Reviewed Original Research Articles

  1. He X, Dahlbäck B. Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S. Eur J Biochem 217(3):857-65, 11/1993. PMID: 8223642.
  2. He X, Dahlbäck B. Rabbit plasma, unlike its human counterpart, contains no complex between protein S and C4b-binding protein. Thromb Haemost 71(4):446-51, 4/1994. PMID: 8052961.
  3. Malm J, He X, Bjartell A, Shen L, Abrahamssson PA and Dahlbäck B. Vitamin K-dependent protein S in Leydig cells of human testis. Biochemical Journal 1993(217):857-886, 9/1994.
  4. Malm J, He X H, Bjartell A, Shen L, Abrahamsson PA, Dahlbäck B. Vitamin K-dependent protein S in Leydig cells of human testis. Biochem J 302 ( Pt 3):845-50, 9/1994. PMCID: PMC1137307.
  5. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94(6):2521-4, 12/1994. PMCID: PMC330087.
  6. He X, Shen L, Dahlbäck B. Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity. Eur J Biochem 227(1-2):433-40, 1/1995. PMID: 7851419.
  7. He X, Shen L, Bjartell A, Dahlbäck B. The gene encoding vitamin K-dependent anticoagulant protein S is expressed in multiple rabbit organs as demonstrated by northern blotting, in situ hybridization, and immunohistochemistry. J Histochem Cytochem 43(1):85-96, 1/1995. PMID: 7822769.
  8. Zöller B, He X, Dahlbäck B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 73(5):743-5, 5/1995. PMID: 7482396.
  9. He X, Shen L, Bjartell A, Malm J, Lilja H, Dahlbäck B. The gene encoding vitamin K-dependent anticoagulant protein C is expressed in human male reproductive tissues. J Histochem Cytochem 43(6):563-70, 6/1995. PMID: 7769227.
  10. Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X, Rezaie AR, Esmon CT. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 271(29):17491-8, 7/1996. PMID: 8663475.
  11. He X, Shen L, Malmborg AC, Smith KJ, Dahlback B, Linse S. Binding site for C4b-binding protein in vitamin K-dependent protein S fully contained in carboxy-terminal laminin-G-type repeats. A study using recombinant factor IX-protein S chimeras and surface plasmon resonance. Biochemistry 36(12):3745-54, 3/1997. PMID: 9132028.
  12. Nyberg P, He X, Härdig Y, Dahlback B, García de Frutos P. Stimulation of Sky tyrosine phosphorylation by bovine protein S--domains involved in the receptor-ligand interaction. Eur J Biochem 246(1):147-54, 5/1997. PMID: 9210477.
  13. He X, Ye J, Esmon CT, Rezaie AR. Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry 36(29):8969-76, 7/1997. PMID: 9220985.
  14. Shen L, He X, Dahlbäck B. Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system. Thromb Haemost 78(3):1030-6, 9/1997. PMID: 9308749.
  15. Borgström A, He X, Axelson J. Stimulation with cholecystokinin leads to increased ratio between mRNA levels for anionic and cationic trypsinogen in rat pancreas. J Gastroenterol 32(6):797-800, 12/1997. PMID: 9430019.
  16. Rezaie AR, He X, Esmon CT. Thrombomodulin increases the rate of thrombin inhibition by BPTI. Biochemistry 37(2):693-9, 1/1998. PMID: 9425093.
  17. Rezaie AR, He X and Esmon CT. Thrombomodulin increases the rate of thrombin inhibition by BPTI. Biochemistry 37(2):693-699, 8/1998.
  18. He X, Shen L, Villoutreix BO, Dahlbäck B. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem 273(42):27449-58, 10/1998. PMID: 9765274.
  19. He X and Rezaie AR. Identification and characterization of the sodium-binding site of activated protein C. J Biol Chem 274(8):4970-6, 2/1999. PMID: 9988741.
  20. Rezaie AR and He X. Sodium binding site of factor Xa: role of sodium in the prothrombinase complex. Biochemistry 39(7):1817-25, 2/2000. PMID: 10677232.
  21. Petty JK, He K, Corless CL, Vetto JT, Weinberg AD. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 183(5):512-8, 5/2002. PMID: 12034383.
  22. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 125(6):884-94, 6/2006. PMID: 16690488.
  23. Young KH, Chan WC, Fu K, Iqbal J, Sanger WG, Ratashak A, Greiner TC, Weisenburger DD. Mantle cell lymphoma with plasma cell differentiation. Am J Surg Pathol 30(8):954-61, 8/2006. PMID: 16861965.
  24. Zhao XF, Young KH, Frank D, Goradia A, Glotzbecker MP, Pan W, Kersun LS, Leahey A, Dormans JP, Choi JK. Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases. Am J Clin Pathol 127(1):47-54, 1/2007. PMID: 17145622.
  25. Young KH, Weisenburger DD, Dave BJ, Smith L, Sanger W, Iqbal J, Campo E, Delabie J, Gascoyne RD, Ott G, Rimsza L, Müller-Hermelink HK, Jaffe ES, Rosenwald A, Staudt LM, Chan WC, Greiner TC. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 110(13):4396-405, 12/2007. e-Pub 9/2007. PMCID: PMC2234786.
  26. Young KH, Xie Q, Zhou G, Eickhoff JC, Sanger WG, Aoun P, Chan WC. Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event. Am J Clin Pathol 129(1):157-66, 1/2008. PMID: 18089500.
  27. Young KH, Chan WC, Fu K, Sanger WG, Picking DL, Greiner TC, and Weisenburger DD. Nodular Mantle Cell Lymphoma with Plasma Cell Differentiation: A New Morphologic Variant. Helix Oncology Review 12(2):10-16, 6/2008.
  28. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, Orlowski RZ. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14(17):5416-25, 9/2008. PMCID: PMC2576518.
  29. Young KH, Leroy K, Møller MB, Colleoni GW, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112(8):3088-98, 10/2008. e-Pub 6/2008. PMCID: PMC2569165.
  30. d'Amore F, Chan E, Iqbal J, Geng H, Young KH, Xiao L, Hess MM, Sanger WG, Smith L, Wiuf C, Hagberg O, Fu K, Chan WC, Dave BJ. Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res 14(22):7180-7, 11/2008. PMID: 19010834.
  31. Wozniak RJ, Keles S, Lugus JJ, Young KH, Boyer ME, Tran TM, Choi K, Bresnick EH. Molecular hallmarks of endogenous chromatin complexes containing master regulators of hematopoiesis. Mol Cell Biol 28(21):6681-94, 11/2008. e-Pub 9/2008. PMCID: PMC2573226.
  32. Hudnall SD, Chen T, Amr S, Young KH, Henry K. Detection of human herpesvirus DNA in Kikuchi-Fujimoto disease and reactive lymphoid hyperplasia. Int J Clin Exp Pathol 1(4):362-8, 2008. e-Pub 1/2008. PMCID: PMC2480545.
  33. Young KH, Zhang D, Malik JT, Williams EC. Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy. Int J Clin Exp Pathol 1(2):185-97, 2008. e-Pub 1/2008. PMCID: PMC2480557.
  34. Xie Q, Chen L, Fu K, Harter J, Young KH, Sunkara J, Novak D, Villanueva-Siles E, Ratech H. Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas. Int J Clin Exp Pathol 1(3):276-84, 2008. e-Pub 1/2008. PMCID: PMC2480560.
  35. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7:40, 2008. e-Pub 5/2008. PMCID: PMC2408930.
  36. Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF, Fleming MD. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 113(6):1304-14, 2/2009. e-Pub 12/2008. PMCID: PMC2637193.
  37. Chang H, Qi C, Trieu Y, Jiang A, Young KH, Chesney A, Jani P, Wang C, Reece D, Chen C. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma 9(1):36-8, 3/2009. PMID: 19362968.
  38. Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Lambotte O, Uccella S, Pinotti G, Pruneri G, Martinelli G, Young KH, Tibiletti MG, Rinaldi A, Zucca E, Kwee I, Bertoni F. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol 151(3):221-31, 11/2010. e-Pub 8/2010. PMID: 20813005.
  39. Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, Fleming MD, Young KH, Pitot H, Zhang J. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 116(26):5991-6002, 12/2010. e-Pub 10/2010. PMCID: PMC3031386.
  40. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, Tang W, Gumperz JE, Kenney SC. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85(1):165-77, 1/2011. e-Pub 10/2010. PMCID: PMC3014199.
  41. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R, Li Y. miR-301a as an NF-kB activator in pancreatic cancer cells. EMBO J 30(1):57-67, 1/2011. e-Pub 11/2010. PMCID: PMC3020116.
  42. Yang DT, Quann PJ, Petrich AM, Leith CP, Young KH, Kahl BS. Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma. Appl Immunohistochem Mol Morphol 19(1):62-9, 1/2011. PMCID: PMC3040491.
  43. Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 152(3):284-94, 2/2011. e-Pub 12/2010. PMID: 21121903.
  44. Visco C, Hoeller S, Malik JT, Xu-Monette ZY, Wiggins ML, Liu J, Sanger WG, Liu Z, Chang J, Ranheim EA, Gradowski JF, Serrano S, Wang HY, Liu Q, Dave S, Olsen B, Gascoyne RD, Campo E, Swerdlow SH, Chan WC, Tzankov A, Young KH. Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am J Surg Pathol 35(2):177-89, 2/2011. PMCID: PMC3079277.
  45. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, Arcaini L, Lucioni M, Rocque GB, Xu-Monette ZY, Visco C, Chang J, Chigrinova E, Forconi F, Marasca R, Besson C, Papadaki T, Paulli M, Larocca LM, Pileri SA, Gattei V, Bertoni F, Foà R, Young KH, Gaidano G. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117(12):3391-401, 3/2011. e-Pub 1/2011. PMID: 21266718.
  46. Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ, Meline B, Du J, Young KH, Ranheim E, Chang Q, Zhang J. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood 118(2):368-79, 7/2011. e-Pub 5/2011. PMCID: PMC3138689.
  47. Montes-Moreno S, Martinez N, Sanchez-Espiridión B, Díaz Uriarte R, Rodriguez ME, Saez A, Montalbán C, Gomez G, Pisano DG, García JF, Conde E, Gonzalez-Barca E, Lopez A, Mollejo M, Grande C, Martinez MA, Dunphy C, Hsi ED, Rocque GB, Chang J, Go RS, Visco C, Xu-Monette Z, Young KH, Piris MA. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 118(4):1034-40, 7/2011. e-Pub 6/2011. PMID: 21633089.
  48. Zhang J, Guy MJ, Norman HS, Chen YC, Xu Q, Dong X, Guner H, Wang S, Kohmoto T, Young KH, Moss RL, Ge Y. Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. J Proteome Res 10(9):4054-65, 9/2011. e-Pub 7/2011. PMCID: PMC3170873.
  49. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 36(4):612-9, 4/2012. PMID: 22314191.
  50. Papathomas TG, Venizelos I, Dunphy CH, Said JW, Wang ML, Campo E, Swerdlow SH, Chan JC, Bueso-Ramos CE, Weisenburger DD, Medeiros LJ, Young KH. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol 43(4):467-80, 4/2012. e-Pub 1/2012. PMID: 22221705.
  51. Aladily TN, Medeiros LJ, Amin MB, Haideri N, Ye D, Azevedo SJ, Jorgensen JL, de Peralta-Venturina M, Mustafa EB, Young KH, You MJ, Fayad LE, Blenc AM, Miranda RN. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol 36(7):1000-8, 7/2012. PMID: 22613996.
  52. Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosía SG, Mazorra F, Castillo ME, Lopez M, Pajares R, García JF, Mollejo M, Camacho FI, Ruiz-Marcellán C, Adrados M, Ortiz N, Franco R, Ortiz-Hidalgo C, Suarez-Gauthier A, Young KH, Piris MA. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 25(7):968-82, 7/2012. e-Pub 4/2012. PMID: 22538516.
  53. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. e-Pub 6/2012. PMID: 22677155.
  54. Takwi AA, Li Y, Becker Buscaglia LE, Zhang J, Choudhury S, Park AK, Liu M, Young KH, Park WY, Martin RC, Li Y. A statin-regulated microRNA represses human c-Myc expression and function. EMBO Mol Med 4(9):896-909, 9/2012. e-Pub 8/2012. PMCID: PMC3491823.
  55. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103-13, 9/2012. e-Pub 3/2012. PMID: 22437443.
  56. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3460-7, 10/2012. e-Pub 6/2012. PMID: 22665537.
  57. Hu S, Young KH, Konoplev SN, Medeiros LJ. Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol 43(11):1789-98, 11/2012. e-Pub 9/2012. PMID: 22959759.
  58. Kanagal-Shamanna S, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, Penn GM, Young KH, You MJ, Bassett J, and Miranda RN. Mature Diffuse B-cell Lymphomas with Blastoid Morphology: A Heterogeneous Group with Predominantly Germinal Center Phenotype and Frequent BCL2 and/or MYC Gene Rearrangements. AJSP 61(5):945-954, 2012.
  59. Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, Swerdlow SH, Rosenwald A, Ott G, Said J, Dunphy CH, Bueso-Ramos CE, Lin P, Wang M, Miranda RN, Tzankov A, Medeiros LJ, Young KH. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol 44(1):110-21, 1/2013. e-Pub 8/2012. PMCID: PMC3640316.
  60. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH. Patients with diffuse large B cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98(2):255-63, 2/2013. e-Pub 8/2012. PMCID: PMC3561433.
  61. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH . CD30 expression defines a novel subgroup of diffuse large B- cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715-24, 4/2013. e-Pub 1/2013. PMCID: PMC3700465.
  62. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20):4021-31; quiz 4250, 5/2013. e-Pub 2/2013. PMCID: PMC3709650.
  63. Loo EY, Medeiros LJ, Aladily TN, Hoehn D, Kanagal-Shamanna R, Young KH, Lin P, Bueso-Ramos CE, Manning JT, Patel K, Thomazy V, Brynes RK, Goswami M, Fayad LE, Miranda RN. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol 37(8):1290-7, 8/2013. PMID: 23774171.
  64. Rinaldi A, Kwee I, Young KH, Zucca E, Gaidano G, Forconi F, Bertoni F. Genome-wide high resolution DNA profiling of hairy cell leukaemia. Br J Haematol 162(4):566-9, 8/2013. e-Pub 5/2013. PMID: 23692203.
  65. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 9/2013. e-Pub 4/2013. PMID: 23545991.
  66. Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol 88(9):798-802, 9/2013. e-Pub 6/2013. PMID: 23695956.
  67. Chou FP, Chen YW, Zhao XF, Xu-Monette ZY, Young KH, Gartenhaus RB, Wang JK, Kataoka H, Zuo AH, Barndt RJ, Johnson M, Lin CY. Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas. Am J Pathol 183(4):1306-17, 10/2013. PMCID: PMC3791685.
  68. Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 122(15):2630-40, 10/2013. e-Pub 8/2013. PMCID: PMC3952598.
  69. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbò F, Piva R, Rancoita PM, Matolcsy A, Timar B, Tousseyn T, Rodríguez-Pinilla SM, Piris MA, Beà S, Campo E, Bhagat G, Swerdlow SH, Rosenwald A, Ponzoni M, Young KH, Piccaluga PP, Dummer R, Pileri S, Zucca E, Inghirami G, Bertoni F. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood 122(15):2683-93, 10/2013. e-Pub 9/2013. PMID: 24004669.
  70. Jain P, Le X, Young KH, Patel KP, Wang S, Pei L, Barron LL, Abruzzo L, O'Brien S. Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 13(5):606-9, 10/2013. e-Pub 6/2013. PMID: 23763914.
  71. Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122(15):2673-82, 10/2013. e-Pub 9/2013. PMID: 24004666.
  72. Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol 66(11):956-61, 11/2013. e-Pub 6/2013. PMID: 23775435.
  73. Wang S, Tzankov A, Xu-Monette ZY, Hoeller S, Wang SA, Richards KL, Zhang S, Said JW, Medeiros LJ, Young KH. Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. Hum Pathol 44(12):2658-67, 12/2013. e-Pub 9/2013. PMID: 24071012.
  74. Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH, Patel K, Medeiros LJ, Garcia-Manero G, Wang SA. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 28(1):185-9, 1/2014. e-Pub 6/2013. PMID: 23787392.
  75. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 32(2):114-20, 1/2014. e-Pub 12/2013. PMCID: PMC4062709.
  76. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma 55(3):624-7, 3/2014. e-Pub 8/2013. PMCID: PMC4188389.
  77. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123(17):2645-51, 4/2014. e-Pub 3/2014. PMCID: PMC4067498.
  78. Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X, Zhao Y, Young KH, Hu W, Feng Z. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget 5(9):2635-47, 5/2014. PMCID: PMC4058033.
  79. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Dybaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJ, Farnen JP, Møller MB, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KH. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20(9):2338-49, 5/2014. e-Pub 2/2014. PMCID: PMC4014309.
  80. Gordon MW, Yan F, Zhong X, Mazumder PB, Xu-Monette ZY, Zou D, Young KH, Ramos KS, Li Y. Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. Mol Carcinog. e-Pub 5/2014. PMCID: PMC4223015.
  81. Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest 124(6):2762-73, 6/2014. e-Pub 5/2014. PMCID: PMC4038579.
  82. Ok CY, Xu-Monette ZY, Tzankov A, O'Malley DP, Montes-Moreno S, Visco C, Møller MB, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Han van Krieken J, Ponzoni M, Farnen JP, Piris MA, Winter JN, Medeiros LJ, Young KH. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer 120(12):1818-29, 6/2014. e-Pub 3/2014. PMID: 24648050.
  83. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Ponzoni M, Ferreri AJ, Ye Q, Winter JN, Farnen JP, Piris MA, Møller MB, You MJ, McDonnell T, Medeiros LJ, Young KH. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 27(7):958-71, 7/2014. e-Pub 12/2013. PMID: 24336156.
  84. Zhang LN, Wang L, Fang C, Zou ZJ, Fan L, Zhang R, Young KH, Li JY, Xu W. The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. Leuk Lymphoma:1-6. e-Pub 7/2014. PMID: 24898664.
  85. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 8/2014. e-Pub 7/2014. PMID: 25073777.
  86. Wang S, Medeiros LJ, Xu-Monette ZY, Zhang S, O'Malley DP, Orazi A, Zuo Z, Bueso-Ramos CE, Yin CC, Liu Z, Miranda RN, Young KH. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol 18(4):203-9, 8/2014. e-Pub 4/2014. PMID: 24852241.
  87. Chang YI, Damnernsawad A, Allen LK, Yang D, Ranheim EA, Young KH, Zhang J, Kong G, Wang J, Liu Y, Fu HY, Yang CS, Guo J, Song H, Zhang J. Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation. Br J Haematol 166(3):461-5, 8/2014. e-Pub 4/2014. PMCID: PMC4107140.
  88. Han L, Zhang M, Li L, Zhang L, Wu J, Li X, Wang X, Young KH, Fu X, Ma W, Sun Z, Zhang X, Chang Y, Qiao Z. Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. Oncol Lett 8(2):886-890, 8/2014. e-Pub 5/2014. PMCID: PMC4081409.
  89. Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T, Jiang W, Xia Z, Young KH. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol 93(9):1541-9, 9/2014. e-Pub 4/2014. PMID: 24782120.
  90. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res 20(19):5113-23, 10/2014. e-Pub 8/2014. PMCID: PMC4184926.
  91. Odqvist L, Montes-Moreno S, Sánchez-Pacheco RE, Young KH, Martín-Sánchez E, Cereceda L, Sánchez-Verde L, Pajares R, Mollejo M, Fresno MF, Mazorra F, Ruíz-Marcellán C, Sánchez-Beato M, Piris MA. NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Mod Pathol 27(10):1331-7, 10/2014. e-Pub 3/2014. PMID: 24603590.
  92. Liu J, Zhang C, Wang XL, Ly P, Belyi V, Xu-Monette ZY, Young KH, Hu W, Feng Z. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ 21(11):1792-804, 11/2014. e-Pub 8/2014. PMCID: PMC4211364.
  93. Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, Liu Z, Lin K, Xu-Monette ZY, Young KH, Liu J, Shen Z, Feng Z, Hu W. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun 5:5218, 2014. e-Pub 10/2014. PMCID: PMC4203416.
  94. Dybkær K, Bøgsted M, Falgreen S, Bødker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, Møller MB, Samworth RJ, Shah RD, Johansen P, El-Galaly TC, Young KH, Johnsen HE. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol 33(12):1379-88, 4/2015. e-Pub 3/2015. PMCID: PMC4397280.
  95. Liu Z, Medeiros LJ, Young KH. Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis. Hematol Oncol. e-Pub 4/2015. PMID: 25921311.
  96. Lu TX, Fan L, Wang L, Wu JZ, Miao KR, Liang JH, Gong QX, Wang Z, Young KH, Xu W, Zhang ZH, Li JY. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget. e-Pub 5/2015. PMID: 26158410.
  97. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma - is it necessary? Oncotarget 6(16):13935-13946, 6/2015. PMID: 26101854.
  98. Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber D, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros JL, Young KH. Crystal-Storing Histiocytosis: A Clinicopathologic Study of 13 Cases. Histopathology. e-Pub 6/2015. PMID: 26118455.
  99. Visco C, Falisi E, Young KH, Pascarella M, Perbellini O, Carli G, Novella E, Rossi D, Giaretta I, Cavallini C, Scupoli MT, De Rossi A, D'Amore ES, Rassu M, Gaidano G, Pizzolo G, Ambrosetti A, Rodeghiero F. Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. Oncotarget. e-Pub 6/2015. PMID: 26087198.
  100. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH. Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 6(16):14720, 6/2015. PMID: 26116824.
  101. Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. e-Pub 6/2015. PMID: 26111978.
  102. Hatanpaa KJ, Fuda F, Koduru P, Young KH, Lega B, Chen W. Lymphomatosis Cerebri: A Diagnostic Challenge. JAMA Neurol. e-Pub 7/2015. PMID: 26147788.
  103. Magnoli F, Ricotti I, Novario M, Mazzucchelli L, Dainese E, Ambrosiani L, Sessa F, Uccella S. Primary testicular diffuse large B-cell lymphoma: morphological and immunophenotypical study with characterization of the T-cell component of the tumor microenvironment. Leuk Lymphoma:1-3. e-Pub 7/2015. PMID: 26033285.
  104. Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, O'Malley DP, Medeiros LJ, Young KH. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. e-Pub 8/2015. PMID: 26248897.
  105. Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Am J Surg Pathol 39(8):1132-9, 8/2015. PMID: 25828391.
  106. Brauner S, Zhou W, Backlin C, Green TM, Folkersen L, Ivanchenko M, Löfström B, Xu-Monette ZY, Young KH, Møller Pedersen L, Boe Møller M, Sundström C, Enblad G, Baecklund E, Wahren-Herlenius M. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. J Intern Med 278(3):323-32, 9/2015. e-Pub 5/2015. PMID: 25880119.
  107. Falgreen S, Dybkær K, Young KH, Xu-Monette ZY, El-Galaly TC, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Bøgsted M. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer 15:235, 2015. e-Pub 4/2015. PMCID: PMC4396063.
  108. Ma X, Conklin DJ, Li F, Dai Z, Hua X, Li Y, Xu-Monette ZY, Young KH, Xiong W, Wysoczynski M, Sithu SD, Srivastava S, Bhatnagar A, Li Y. The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun 6:7151, 2015. e-Pub 5/2015. PMCID: PMC4440243.
  109. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 8:45, 2015. e-Pub 5/2015. PMCID: PMC4431603.
  110. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8(1):74, 2015. e-Pub 6/2015. PMCID: PMC4487966.
  111. Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Li Zhang, Carlo Visco, Karen Dybkaer, Lihui Yin, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, J. Han van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Ben M. Parsons, Xiaoying Zhao Jane N. Winter, Miguel A. Piris, Timothy McDonnell, Roberto N. Miranda, Yong Li, Medeiros LJ, and Young KH. Clinical features, tumor biology and prognosis associated with MYC rearrangement and overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology. 2015 Accepted.
  112. Deng L, Xu-Monette ZY, Loghavi SN, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L, Dybkær K, Chiu A, Perry AM, Zhang S, Tzankov A, Rao H, Abramson J, Sohani AR, Xu M, His ED, Zhu J, Ponzoni M, Wang S, Zhang M, Ferreri AJM, Parsons BM, Piris MA, Li Y, Medeiros LJ, Young KH. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: A report from the International PTL Consortium. Leukemia 2015 Accepted.
  113. Li L, Xu-Monette ZY, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkaer K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH. Prognostic Impact of c-Rel Nuclear Expression and REL amplification and Crosstalk between c-Rel and the p53 Pathway in Diffuse Large B-Cell. Oncotarget. 2015 In Press.







Autoimmune Journal Flyer